Adverse events in rheumatoid arthritis patient with etanercept therapy: The appearance of osteomalacia;Complicanze in corso di artrite reumatoide in trattamento con etanercept: La comparsa di una sindrome osteomalacica

Recenti Progressi in Medicina

Volumn 96, Issue 11, 2005, Pages 552-555

  D'Amore, Massimo ^a,b   Minenna, Giovanna ^a   D'Amore, Simona ^a  

^a Sezione di Medicine Interna DIMIMP   (Italy)

^b Sezione di Medicine Interna DIMIMP ^*  (Italy)

Author keywords

Etanercept; Osteomalacia; Rheumatoid arthritis

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE;

ARTICLE; AUTOIMMUNE DISEASE; BONE MINERALIZATION; HUMAN; OSTEOMALACIA; PATHOPHYSIOLOGY; RHEUMATOID ARTHRITIS; RICKETS; SYNOVIUM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; ISOXAZOLES; METHOTREXATE; MIDDLE AGED; OSTEOMALACIA; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 30344453944     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sommer OJ, Kladosek A, Weiler V, Czembirek H, Boeck M, Stiskal M. Rheumatoid arthritis: a practical guide to state-of-the-art imaging, image interpretation, and clinical implications. Radiographics 2005; 25: 381-98.
2. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130-6.
3. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-19.
4. Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF. Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study. Scand J Rheumatol 2004; 33: 380-4.
5. Bukhari MAS, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years. Results from a large observational inception study. Arthritis and Rheumatism 2003; 48: 46-53.
6. Romano C, De Filippis L, Caliri A, Lo Gullo R, Bagnato G. L'approccio terapeutico con DMARD's nell'artrite reumatoide. Reumatismo 2004; 56: 46-7.
7. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
8. Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003; 42: 1189-96.
9. Galeazzi M, Foti R, Bellisai F, Leopardi R. La leflunomide: recenti acquisizioni. Reumatismo 2004; 56: 41-4.
10. Imperato AK, Bingham III CO, Abramson SB. Overview of benefit/risk of biological agents. Clin and Exp Rheum 2004; 22 (suppl 35): S-108-14.
11. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004; 26: 1960-75.
12. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3783-91.
13. Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 2004; 22 (suppl 35): S77-82.
14. Takeuchi Y. Treatment with vitamin D metabolites for rickets/ osteomalacia. Clin Calcium 2003; 13: 930-3.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. Kanberoglu K, Kantarci F, Cebi D, Yilmaz MH, Kurugoglu S, Bilici A, Koyuncu H. Magnetic resonance imaging in osteomalacic insufficiency fractures of the pelvis. Clin Radiol 2005; 60: 105-11.
17. Bernecker PM. Osteomalacia and rickets. Wien Med Wochenschr 2004; 154: 102-6.
18. Taxel P, Kenny A. Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone 2000; 2: 11-21.
19. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-TNFalpha treatment. Ann Rheum Dis 2005; 764: 1137-40
20. Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 777-80.